NDAORALTABLET
Approved
Mar 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEEBACIN (aminosalicylate sodium) is an oral tablet indicated for tuberculosis treatment, representing a legacy small-molecule antimycobacterial agent. Approved in 1950, it functions as a second-line TB therapy with a well-established but narrow clinical role.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) signals a contracting brand team and shift toward generic manufacturing operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities on TEEBACIN center on manufacturing scale, process optimization, and clinical operations support—not commercial expansion. This is a defensive, legacy-product portfolio role suited to specialists focused on operational excellence and regulatory compliance rather than growth.
DirectorEngineer
Worked on TEEBACIN at Century Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.